Humanity will reach a critical milestone when we can rapidly reprogram and re-engineer biological systems to sustainably manufacture new medicines, grow food, biofuels and countless other products – the dream of synthetic biology since it first emerged. While some estimates put the value of the bioeconomy at nearly one trillion dollars, we are not there yet. Fundamental obstacles remain in the design, build, test, and learn cycles that are pivotal to iterating and developing new synthetic biology-based products. Hear from synbio experts on efforts to overcome the biggest challenges impeding the development of synthetic DNA for biomanufacturing. Learn how new investment initiatives from the US government will impact this essential and growing field over the next few decades and add significant value to not only the biotech and pharma industries but humanity as a whole as synbio helps address some of our biggest challenges.